Fate Therapeutics, Inc. (FATE)
Stock Price:
$57.13 USD
1.86 (3.37%)
Updated November 25, 4:00 PM EST - Market closed
After-hours: $57.25 +0.12 (0.21%) Nov 25, 6:45 PM
Key Info
| Market Cap |
4.98B |
| Revenue (ttm) |
18.34M |
| Net Income (ttm) |
-148.58M |
| Shares Out |
87.24M |
| EPS (ttm) |
-1.87 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| Dividend |
n/a |
| Dividend Yield |
n/a |
Stock Quote
| Trading Day |
November 25 |
| Last Price |
$57.13 |
| Previous Close |
$55.27 |
| Change ($) |
1.86 |
| Change (%) |
3.37% |
| Day's Open |
55.27 |
| Day's Range |
54.61 - 57.15 |
| Day's Volume |
568,348 |
| 52-Week Range |
13.26 - 57.15 |
More Stats
| Market Cap |
4.98B |
| Enterprise Value |
4.57B |
| Earnings Date (est) |
Mar 8, 2021 |
| Ex-Dividend Date |
n/a |
| Shares Outstanding |
87.24M |
| Float |
81.38M |
| EPS (basic) |
-1.85 |
| EPS (diluted) |
-1.87 |
| FCF / Share |
-0.57 |
| Dividend |
n/a |
| Dividend Yield |
n/a |
| Earnings Yield |
n/a |
| FCF Yield |
n/a |
| Payout Ratio |
n/a |
| Shares Short |
14.35M |
| Short Ratio |
16.56 |
| Short % of Float |
17.63% |
| Beta |
1.76 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| P/FCF Ratio |
n/a |
| PS Ratio |
271.77 |
| PB Ratio |
10.82 |
| Revenue |
18.34M |
| Operating Income |
-123.76M |
| Net Income |
-148.58M |
| Free Cash Flow |
-49.35M |
| Net Cash |
418.55M |
| Net Cash / Share |
4.80 |
| Gross Margin |
-420.34% |
| Operating Margin |
-674.83% |
| Profit Margin |
-810.10% |
| FCF Margin |
-269.08% |
| ROA |
-16.00% |
| ROE |
-42.92% |
| ROIC |
-58.60% |
Stats based on trailing-twelve-month (ttm) numbers.
Analyst Forecasts
Analyst Ratings (14)
| Buy |
12 |
| Overweight |
0 |
| Hold |
2 |
| Underweight |
0 |
| Sell |
0 |
Price Target
$54.36*
(-4.85% downside)
Low
30.0
Current: $57.13
High
71.0
Target: 54.36
*Average 12-month price target from 14 stock analysts.
Financial Performance
Financial numbers in millions USD.
Financial Overview
| Year | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|
| Revenue | 10.68 | 4.74 | 4.11 | 4.40 | 2.43 | - | 0.97 | 2.67 | 1.17 |
| Revenue Growth | 125.32% | 15.44% | -6.72% | 81.08% | - | - | -63.63% | 128.21% | - |
| Gross Profit | 10.68 | 4.74 | 4.11 | 4.40 | 2.43 | - | 0.97 | 2.67 | 1.17 |
| Operating Income | -101 | -67.09 | -42.13 | -31.96 | -27.78 | -24.90 | -17.68 | -13.56 | -13.29 |
| Net Income | -98.15 | -66.60 | -42.95 | -33.46 | -29.99 | -25.88 | -20.89 | -14.24 | -13.43 |
| Shares Outstanding | 68.19 | 56.20 | 41.98 | 31.75 | 25.48 | 20.45 | 5.90 | 1.09 | 0.83 |
| Earnings Per Share | -1.44 | -1.19 | -1.02 | -1.05 | -1.18 | -1.27 | -3.54 | -13.06 | -16.16 |
| Operating Cash Flow | -83.18 | -38.65 | -36.82 | -29.82 | -18.40 | -22.42 | -15.37 | -13.27 | -12.15 |
| Capital Expenditures | -7.40 | -2.30 | -1.73 | -0.44 | -1.50 | -0.88 | -0.24 | -0.71 | 0.20 |
| Free Cash Flow | -90.57 | -40.95 | -38.54 | -30.26 | -19.90 | -23.30 | -15.61 | -13.98 | -11.95 |
| Cash & Equivalents | 222 | 201 | 101 | 92.23 | 64.93 | 49.22 | 54.16 | 9.21 | 6.51 |
| Total Debt | 26.93 | 14.88 | 14.81 | 10.69 | 18.24 | 19.61 | 1.73 | 3.67 | 4.84 |
| Net Cash / Debt | 195 | 186 | 86.26 | 81.55 | 46.69 | 29.62 | 52.43 | 5.54 | 1.67 |
| Assets | 302 | 213 | 105 | 95.05 | 67.96 | 51.18 | 55.58 | 11.08 | 7.85 |
| Liabilities | 57.52 | 52.56 | 28.10 | 21.89 | 29.92 | 22.84 | 4.74 | 63.90 | 58.54 |
| Book Value | 245 | 160 | 77.19 | 73.15 | 38.04 | 28.34 | 50.85 | -52.83 | -50.68 |
Numbers in millions USD, except per-share numbers.
Company Details
| Full Name |
Fate Therapeutics, Inc. |
| Country |
United States |
| Employees |
178 |
| CEO |
J. Scott Wolchko |
Stock Information
| Ticker Symbol |
FATE |
| Stock Exchange |
NASDAQ |
| Sector |
Healthcare |
| Industry |
Biotechnology |
| Unique Identifier |
NASDAQ: FATE |
| IPO Date |
October 1, 2013 |
Description
Fate Therapeutics, a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. Its NK- and T-cell immuno-oncology programs under development includes FT516 for the treatment of acute myeloid leukemia (AML) and B-cell lymphoma, FT596 to treat B-cell lymphoma and CLL, FT538 to treat AML and multiple myeloma, FT576 to treat multiple myeloma, FT819 to treat B-cell malignancies, and FT-ONO1 to treat hematologic malignancies; and FT500, FT516, and FT-ONO2 for the treatment of advanced solid tumors. The company's NK- and T-cell immuno-oncology programs under development also includes ProTmune for the treatment of hematologic malignancies; FATE-NK100 for the treatment of recurrent ovarian cancer; and FATE-NK100 for the treatment of advanced solid tumors. The company has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd. for the development and commercialization of two off-the-shelf iPSC-derived CAR T-cell product candidates; strategic research collaboration and license agreement with Juno Therapeutics, Inc. to screen for and identify small molecule modulators that enhance the therapeutic properties of genetically-engineered T-cell immunotherapies; and a collaboration and option agreement with Janssen Biotech, Inc. Fate Therapeutics, Inc. was founded in 2007 and is headquartered in San Diego, California.